Cowan Elvia 4

What Happened Elvia Cowan, Senior Vice President, Finance & Chief Accounting Officer of Vaxcyte (PCVX), sold a total of 1,892 shares on March 17, 2026 in two open-market transactions. She sold 1,487 shares at a reported weighted-average price of $55.39 for $82,360, and 405 shares at a reported weighted-average price of $56.26 for $22,787 — roughly $105,147 total. These were sales (not purchases), which are often routine dispositions rather than a bullish signal.

Key Details

• Transaction dates: March 17, 2026 (both sales).
• Reported amounts: 1,487 shares @ $55.39 (total $82,360) and 405 shares @ $56.26 (total $22,787); combined 1,892 shares ≈ $105,147.
• Price ranges: first block sold at $54.98–$55.935 (weighted avg reported); second block sold at $56.00–$56.42 (weighted avg reported). The filer says they can provide per-price breakdowns on request.
• Plan/authority: Sales were made pursuant to a Rule 10b5-1 trading plan adopted December 8, 2025 (footnote).
• Lock-up note: No other shares subject to the lock-up agreement dated January 29, 2026 were sold by the reporting person.
• Shares owned after transaction: Not disclosed in the provided Form 4.
• Filing timeliness: Form was filed on March 18, 2026 for trades on March 17, 2026 — no late filing indicated.

Context These were planned open-market sales under a 10b5-1 trading plan, which allows insiders to sell according to pre-set rules and timing; such sales are generally considered routine and do not necessarily reflect a change in the insider’s view of the company. For more detail on holdings or per-price breakdowns, the reporting person has stated they will provide that information upon request to the SEC, the issuer, or security holders.